FOXP1 and cancer: However, in the subgroup analyses based on cancer type (which included DLBCL and MALT lymphoma) and solid tumors (which excluded DLBCL and MALT lymphoma), the pooled results demonstrated that decreased FOXP1 expression had a favorable prognostic value for lymphomas (HR = 0.38, 95%CI: 0.30–0.48, p < 0.001) but an unfavorable prognosis for solid tumors (HR = 1.82, 95%CI: 1.18–2.83, p = 0.007) (Figs 4 and 5).